Kevin A. Nuno

Kevin A. Nuno

Auto-generated profile, based on publicly available information

Kevin A. Nuno

Cancer Biology Graduate Program, Stanford University School of Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MLMiles H. Linde
Miles H. Linde
AFAmy C. Fan
Amy C. Fan
TKThomas Köhnke
Thomas Köhnke
ATAaron C. Trotman-Grant
Aaron C. Trotman-Grant
SGSarah F. Gurev
Sarah F. Gurev
RMRavindra Majeti
Ravindra Majeti
Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAA) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid-lineage reprogramming to directly convert cancer cells into tumor-reprogrammed antigen-presenting cells (TR-APC). Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. Finally, we demonstrate the clinical applicability of this approach by generating TR-APCs from primary clinical specimens and stimulating autologous patient-derived T cells. Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology. Significance: Despite recent advances, the clinical benefit provided by cancer vaccination remains limited. We present a cancer vaccination approach leveraging myeloid-lineage reprogramming of cancer cells into APCs, which subsequently activate anticancer immunity through presentation of self-derived cancer antigens. Both hematologic and solid malignancies derive significant therapeutic benefit from reprogramming-based immunotherapy. This article is highlighted in the In This Issue feature, p. 1027

22 April 2024 in eLife
Verified
Journal Article
Open access
KNKevin Nuno
Kevin Nuno
AAArmon Azizi
Armon Azizi
TKThomas Koehnke
Thomas Koehnke
CLCaleb Lareau
Caleb Lareau
AEAsiri Ediriwickrema
Asiri Ediriwickrema
RMRavindra Majeti
Ravindra Majeti
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.

14 February 2024 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
TKThomas Köhnke
Thomas Köhnke
KNKevin A. Nuno
Kevin A. Nuno
CACatherine C. Alder
Catherine C. Alder
EGEric J. Gars
Eric J. Gars
PPPaul Phan
Paul Phan
RMRavindra Majeti
Ravindra Majeti
Mutations in additional sex combs like 1 (ASXL1) confer poor prognosis both in myeloid malignancies and in premalignant clonal hematopoiesis (CH). However, the mechanisms by which these mutations contribute to disease initiation remain unresolved, and mutation-specific targeting has remained elusive. To address this, we developed a human disease model that recapitulates the disease trajectory from ASXL1-mutant CH to lethal myeloid malignancy. We demonstrate that mutations in ASXL1 lead to the expression of a functional, truncated protein and determine that truncated ASXL1 leads to global redistribution of the repressive chromatin mark H2AK119Ub, increased transposase-accessible chromatin, and activation of both myeloid and stem cell gene-expression programs. Finally, we demonstrate that H2AK119Ub levels are tied to truncated ASXL1 expression levels and leverage this observation to demonstrate that inhibition of the PRC1 complex might be an ASXL1-mutant–specific therapeutic vulnerability in both premalignant CH and myeloid malignancy. Significance: Mutant ASXL1 is a common driver of CH and myeloid malignancy. Using primary human HSPCs, we determine that truncated ASXL1 leads to redistribution of H2AK119Ub and may affect therapeutic vulnerability to PRC1 inhibition.

2 October 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AFAmy C. Fan
Amy C. Fan
YNYusuke Nakauchi
Yusuke Nakauchi
LBLawrence Bai
Lawrence Bai
AAArmon Azizi
Armon Azizi
KNKevin A. Nuno
Kevin A. Nuno
RMRavindra Majeti
Ravindra Majeti
Disease-initiating mutations in the transcription factor RUNX1 occur as germline and somatic events that cause leukemias with particularly poor prognosis. However, the role of RUNX1 in leukemogenesis is not fully understood and effective therapies for RUNX1-mutant leukemias remain elusive. Here, we use primary patient samples and a RUNX1 knockout model in primary human hematopoietic cells to investigate how RUNX1 loss contributes to leukemic progression and to identify targetable vulnerabilities. Surprisingly, we found that RUNX1 loss decreased proliferative capacity and stem cell function. However, RUNX1-deficient cells selectively upregulated the interleukin-3 (IL-3) receptor. Exposure to IL-3, but not other JAK/STAT cytokines, rescued RUNX1 KO proliferative and competitive defects. Further, we demonstrated that RUNX1 loss repressed JAK/STAT signaling and rendered RUNX1-deficient cells sensitive to JAK inhibitors. Our study identifies a dependency of RUNX1-mutant leukemias on IL-3/JAK/STAT signaling, which may enable these aggressive blood cancers to be targeted with existing agents.

4 May 2023
Verified
Other
Open access
PDF file
MLMiles H. Linde
Miles H. Linde
AFAmy C. Fan
Amy C. Fan
TKThomas Köhnke
Thomas Köhnke
ATAaron C. Trotman-Grant
Aaron C. Trotman-Grant
SGSarah F. Gurev
Sarah F. Gurev
RMRavindra Majeti
Ravindra Majeti
TR-APC induction in solid tumor models attenuates tumor growth kinetics and prolongs survival

25 April 2023
Verified
Other
Open access
PDF file
MLMiles H. Linde
Miles H. Linde
AFAmy C. Fan
Amy C. Fan
TKThomas Köhnke
Thomas Köhnke
ATAaron C. Trotman-Grant
Aaron C. Trotman-Grant
SGSarah F. Gurev
Sarah F. Gurev
RMRavindra Majeti
Ravindra Majeti
Summary of clinical features of primary B-ALL specimens